Benefits of GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists for Stroke Reduction in Type 2 Diabetes: A Call to Action for Neurologists

被引：44
作者：
Goldenberg, Ronald M. [1 ]
Cheng, Alice Y. Y. [2 ]
Fitzpatrick, Tess [3 ]
Gilbert, Jeremy D. [4 ]
Verma, Subodh [5 ]
Hopyan, Julia J. [4 ]
机构：
[1] LMC Diabet & Endocrinol, 5-1600 Steeles Ave W, Concord, ON L4K 4M2, Canada
[2] Univ Toronto, St Michaels Hosp, Trillium Hlth Partners, Toronto, ON, Canada
[3] Mackenzie Hlth, Richmond Hill, ON, Canada
[4] Univ Toronto, Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada
[5] Univ Toronto, St Michaels Hosp, Toronto, ON, Canada
来源：
STROKE | 2022年 / 53卷 / 05期
关键词：
diabetes mellitus; type; 2; glucagon-like peptide-1 receptor; hypoglycemic agents; ischemic stroke; PIOGLITAZONE CLINICAL-TRIAL; CARDIOVASCULAR OUTCOMES; MACROVASCULAR EVENTS; SECONDARY PREVENTION; KIDNEY OUTCOMES; ISCHEMIC-STROKE; METAANALYSIS; MELLITUS; MANAGEMENT; RECOMMENDATIONS;
D O I：
10.1161/STROKEAHA.121.038151
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
People living with diabetes are at higher risk for stroke and have a poorer prognosis following a stroke event than those without diabetes. Data from cardiovascular outcome trials and meta-analyses indicate that GLP-1RAs (glucagon-like peptide 1 receptor agonists) reduce the risk of stroke in individuals with type 2 diabetes. Accordingly, many guidelines now recommend the addition of GLP-1RAs to ongoing antihyperglycemic regimens to lower the risk of stroke in type 2 diabetes. The current work summarizes evidence supporting the use of GLP-1RAs for stroke reduction in people with type 2 diabetes and offers 2 new resources for neurologists who are considering GLP-1RAs for their patients-a list of frequently asked questions with evidence-based answers on safely initiating and managing GLP-1RAs, and a practical decision-making algorithm to assist in using GLP-1RAs as part of a stroke reduction strategy.
引用
收藏
页码：1813 / 1822
页数：10
相关论文
共 66 条
[1]   Emerging Technologies for Diabetes Care [J].
Bailey, Timothy S. ;
Walsh, John ;
Stone, Jenine Y. .
DIABETES TECHNOLOGY & THERAPEUTICS, 2018, 20 :78-84
[2]   Glucagon-Like Peptide-1 Receptor Agonists and Prevention of Stroke Systematic Review of Cardiovascular Outcome Trials With Meta-Analysis [J].
Bellastella, Giuseppe ;
Maiorino, Maria Ida ;
Longo, Miriam ;
Scappaticcio, Lorenzo ;
Chiodini, Paolo ;
Esposito, Katherine ;
Giugliano, Dario .
STROKE, 2020, 51 (02) :666-669
[3]   Impact of high glucose levels and glucose lowering on risk of ischaemic stroke: a Mendelian randomisation study and meta-analysis [J].
Benn, Marianne ;
Emanuelsson, Frida ;
Tybjaerg-Hansen, Anne ;
Nordestgaard, Borge G. .
DIABETOLOGIA, 2021, 64 (07) :1492-1503
[4]   Substantial Cardiovascular Benefit from lcosapent Ethyl in Patients with Diabetes: REDUCE-IT DIABETES [J].
Bhatt, Deepak L. ;
Brinton, Eliot A. ;
Miller, Michael ;
Steg, Philippe G. ;
Jacobson, Terry A. ;
Ketchum, Steven B. ;
Doyle, Ralph T. ;
Juliano, Rebecca A. ;
Jiao, Lixia ;
Granowitz, Craig ;
Ganda, Om ;
Welty, Francine K. ;
Busch, Robert S. ;
Goldberg, Anne C. ;
Herrington, David M. ;
Budoff, Matthew ;
Tardif, Jean-Claude ;
Ballantyne, Christie M. .
DIABETES, 2020, 69
[5]   Commentary: Glucose control: Not just a bystander in GLP-1RA-mediated cardiovascular protection [J].
Caruso, Irene ;
Cignarelli, Angelo ;
Natalicchio, Annalisa ;
Perrini, Sebastio ;
Laviola, Luigi ;
Giorgino, Francesco .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2020, 109
[6]   Insulin in the Management of Acute Ischemic Stroke: A Systematic Review and Meta-Analysis [J].
Cerecedo-Lopez, Christian D. ;
Cantu-Aldana, Alejandra ;
Patel, Nirav J. ;
Aziz-Sultan, M. Ali ;
Frerichs, Kai U. ;
Du, Rose .
WORLD NEUROSURGERY, 2020, 136 :E514-E534
[7]   Cardiorenal mechanisms of action of glucagon-like-peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors [J].
Cherney, David Z. I. ;
Udell, Jacob A. ;
Drucker, Daniel J. .
MED, 2021, 2 (11) :1203-1230
[8]  
Collins R, 2009, LANCET, V373, P1849, DOI 10.1016/S0140-6736(09)60503-1
[9]   Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol [J].
Dahlöf, B ;
Devereux, RB ;
Kjeldsen, SE ;
Julius, S ;
Beevers, G ;
de Faire, U ;
Fyhrquist, F ;
Ibsen, H ;
Kristiansson, K ;
Lederballe-Pedersen, O ;
Lindholm, LH ;
Nieminen, MS ;
Omvik, P ;
Oparil, S ;
Wedel, H .
LANCET, 2002, 359 (9311) :995-1003
[10]   2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes [J].
Das, Sandeep R. ;
Everett, Brendan M. ;
Birtcher, Kim K. ;
Brown, Jenifer M. ;
Januzzi, James L., Jr. ;
Kalyani, Rita R. ;
Kosiborod, Mikhail ;
Magwire, Melissa ;
Morris, Pamela B. ;
Neumiller, Joshua J. ;
Sperling, Laurence S. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 76 (09) :1117-1145
1234567